Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol
FEV1 % predicted: absolute change from baseline · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted2 studies · 600 participantsModerate
Findings
What do systematic reviews say?
6 questions · 6 findings · 1 reviews
No studies found 3 · 50%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 33.3%Moderate 1 · 16.7%High 0 · 0%
Summary of findings ‐ Inhaled mannitol vs dornase alfa
FEV1 % predicted · children and young adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
FEV1 % predicted: absolute change from baseline · children and young adults with CF
1 finding from 1 review
- no estimate extracted1 study · 22 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
FEV1 % predicted: absolute change from baseline · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted1261 participantsLow
Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa
FEV1 % predicted · children and young adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
FEV1 · children and young adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found